NASDAQ:GDRX GoodRx (GDRX) Stock Price, News & Analysis $2.92 -0.10 (-3.31%) Closing price 11/20/2026 04:00 PM EasternExtended Trading$2.86 -0.06 (-1.99%) As of 11/20/2026 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About GoodRx Stock (NASDAQ:GDRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get GoodRx alerts:Sign Up Key Stats Today's Range$2.91▼$3.0950-Day Range$2.92▼$3.7252-Week Range$1.77▼$3.89Volume2.01 million shsAverage Volume1.16 million shsMarket Capitalization$1.00 billionP/E Ratio73.02Dividend YieldN/APrice Target$4.15Consensus RatingHold Company Overview GoodRx Holdings, Inc. operates a digital healthcare platform that helps consumers in the United States compare prescription medication prices at pharmacies. Its website and mobile app provide free price comparisons and discounts that consumers can use when paying for eligible prescriptions. The company also offers subscription services, including GoodRx Gold, and provides access to telehealth and other care services through GoodRx Care. Its platform connects consumers with pharmacies and healthcare providers, while its services for pharmaceutical companies include programs that help make medications and savings offers available to patients. Founded in 2011, GoodRx is based in Santa Monica, California. The company’s business focuses on the U.S. healthcare market.AI Generated. May Contain Errors. Read More GoodRx Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks71st Percentile Overall ScoreGDRX MarketRank™: 3.544995794785 of 5 starsGoodRx scored higher than 71% of companies evaluated by MarketBeat, and ranked 214th out of 837 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingGoodRx has received a consensus rating of Hold. The company's average rating score is 2.08, and is based on no strong buy ratings, 4 buy ratings, 6 hold ratings, and 3 sell ratings.Upside PotentialGoodRx has a consensus price target of $4.15, representing about 42.1% upside from its current price of $2.92.Amount of Analyst CoverageGoodRx has only been the subject of 1 research reports in the past 90 days.Read more about GoodRx's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth25.00% Earnings GrowthEarnings for GoodRx are expected to grow by 25.00% in the coming year, from $0.16 to $0.20 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GoodRx is 73.02, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.19.Price to Earnings Ratio vs. SectorThe P/E ratio of GoodRx is 73.02, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 32.56.Price to Book Value per Share RatioGoodRx has a P/B Ratio of 1.61. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about GoodRx's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.11% of the float of GoodRx has been sold short.Short Interest Ratio / Days to CoverGoodRx has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GoodRx has recently decreased by 2.73%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGoodRx does not currently pay a dividend.Dividend GrowthGoodRx does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.37 News SentimentGoodRx has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for GoodRx this week, compared to 3 articles on an average week.Search Interest7 people have searched for GDRX on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added GoodRx to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, GoodRx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,471,274.00 in company stock.Percentage Held by Insiders5.87% of the stock of GoodRx is held by insiders.Percentage Held by Institutions63.77% of the stock of GoodRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about GoodRx's insider trading history. Receive GDRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GoodRx and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GDRX Stock News HeadlinesGoodRx Holdings, Inc. (NASDAQ:GDRX) Stock Has Consensus Target Price of $4.15November 22 at 2:28 AM | americanbankingnews.comFinancial Contrast: GoodRx (GDRX) & Its RivalsNovember 12, 2026 | americanbankingnews.comELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th. A free Masterclass claims to reveal what Musk filed with regulators and why he's working to keep it quiet.November 22 at 1:00 AM | Paradigm Press (Ad)GoodRx stock rises on Google Cloud healthcare AI partnershipNovember 10, 2026 | finance.yahoo.comGoodRx Brings Prescription Pricing Intelligence to Google Cloud’s Gemini for HealthcareNovember 10, 2026 | finance.yahoo.comGoodRx Brings Prescription Pricing Intelligence to Google Cloud's Gemini for HealthcareNovember 10, 2026 | businesswire.comGoodRx Holdings Delays Third-Quarter Report Filing Amid Restatement WorkNovember 10, 2026 | tipranks.com3 Penny Stocks With Revenue Growth Up To 44%November 4, 2026 | uk.finance.yahoo.comSee More Headlines GDRX Stock Analysis - Frequently Asked Questions How have GDRX shares performed this year? GoodRx's stock was trading at $2.71 on January 1st, 2026. Since then, GDRX stock has increased by 7.7% and is now trading at $2.92. How were GoodRx's earnings last quarter? GoodRx Holdings, Inc. (NASDAQ:GDRX) announced its earnings results on Wednesday, August, 5th. The company reported $0.08 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.08 by $0.00. The business's revenue was down 1.3% on a year-over-year basis. Read the conference call transcript. When did GoodRx IPO? GoodRx (GDRX) raised $900 million in an initial public offering on Wednesday, September 23rd 2020. The company issued 34,615,384 shares at a price of $24.00-$28.00 per share. Morgan Stanley, Goldman Sachs, J.P. Morgan and Barclays served as the underwriters for the IPO and BofA Securities, Citigroup, Credit Suisse, RBC Capital Markets, UBS Investment Bank, Cowen, Deutsche Bank Securities, Evercore ISI, Citizens Capital Markets, KKR, LionTree, Raymond James, SVB Leerink, Academy Securities, Loop Capital Markets, R. Seelaus and Ramirez were co-managers. Who are GoodRx's major shareholders? Top institutional investors of GoodRx include Marshall Wace LLP (0.27%), State Street Corp (0.20%), Algert Global LLC (0.19%) and Goldman Sachs Group Inc. (0.12%). Insiders that own company stock include Scott Wagner, Francisco Partners Iv, LP and Equity Vii LP Spectrum. View institutional ownership trends. How do I buy shares of GoodRx? Shares of GDRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of GoodRx own? Based on aggregate information from My MarketBeat watchlists, some other companies that GoodRx investors own include NVIDIA (NVDA), Palantir Technologies (PLTR), Tesla (TSLA), PayPal (PYPL), Block (XYZ), Advanced Micro Devices (AMD) and CrowdStrike (CRWD). Company Calendar Last Earnings8/05/2026Today11/22/2026Next Earnings (Estimated)11/23/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (6m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 GDRX's financial health is in the Green zone, according to TradeSmith. GDRX has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Technology Sub-IndustryHealthcare Technology Current SymbolNASDAQ:GDRX CIK1809519 Webwww.goodrx.com Phone855-268-2822FaxN/AEmployees697Year Founded2011Price Target and Rating Average Price Target for GoodRx$4.15 High Price Target$5.00 Low Price Target$2.75 Potential Upside/Downside+42.1%Consensus RatingHold Rating Score (0-4)2.08 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)$0.04 Trailing P/E Ratio73.02 Forward P/E Ratio14.60 P/E GrowthN/ANet Income$30.44 million Net Margins2.07% Pretax Margin5.27% Return on Equity7.22% Return on Assets2.53% Debt Debt-to-Equity Ratio0.74 Current Ratio1.38 Quick Ratio1.38 Sales & Book Value Annual Sales$785.23 million Price / Sales1.27 Cash Flow$0.40 per share Price / Cash Flow7.30 Book Value$1.81 per share Price / Book1.61Miscellaneous Outstanding Shares342,574,000Free Float322,465,000Market Cap$1.00 billion OptionableOptionable Beta1.66 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:GDRX) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredThe warning signs most investors see too lateDr. Martin D. Weiss has publicly predicted six major American crashes since founding Weiss Ratings in 1971. ...Weiss Ratings | SponsoredA free stock pick, from me to youElon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Withou...Behind the Markets | SponsoredRetirement balance looks fine, so why do you feel behind?Does your retirement balance look fine while you still feel like you're falling behind? On Wednesday, December...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GoodRx Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GoodRx With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.